Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant bevacizumab + XELOX vs XELOX after radical resection of colorectal cancer liver metastases
2006-006072-38Phase 3Terminated
- Sponsor
- Dutch Colorectal Cancer Group
- Start
- Sep 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab in colorectal cancer (CRC) (2 arms), sponsored by Dutch Colorectal Cancer Group. Primary endpoint: Disease-free survival. Started Sep 2007; status: terminated.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2006-006072-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006072-38.